Analysis shows genomic alterations in tumor tissue and plasma DNA in HER2+ patients, indicating treatment response differences.
Supplementary Figure 5. Genomic alterations detected in patients treated in subprotocol Q enrolling patients with HER2 amplifications who received treatment with ado-trastuzumab emtansine. Patients are stratified according to the best overall response. Triangles are used to depict the presence of mutation in tissue (lower triangle) and/or plasma (upper triangle).
No takes yet. Share an insight, caveat, or question.
Gouda et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: